JAK Inhibitor Therapy in the Myeloproliferative Neoplasm Population

During a live virtual event, Ruben Mesa, MD, discussed the use and sequencing of JAK inhibitors and stem cell transplant for patients with myelofibrosis.

During a live virtual event, Ruben Mesa, MD, discussed the clinical trials and challenges of using ruxolitinib for patients with myelofibrosis.

During a Targeted Oncology case-based roundtable event, Pankit Vachhani, MD, discussed with participants how they would diagnose a patient who potentially has primary myelofibrosis.

During a Targeted Oncology case-based roundtable event, Pankit Vachhani, MD, discussed with participants how to assess risk and begin treatment for myelofibrosis. This is the second of 2 articles based on this event.

During a Targeted Oncology case-based roundtable event, Rami Komrokji, MD, and participants discussed when to start treatment for patients with myelofibrosis.

During a Targeted Oncology case-based roundtable event, Rami Komrokji, MD, discussed data supporting the use of ruxolitinib and what role it may play in improving long-term outcomes for patients with myelofibrosis. This is the second of 2 articles based on this event.